Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14444MR)

This product GTTS-WQ14444MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14444MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9985MR IVTScrip™ mRNA-Anti-env, KD-247(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA KD-247
GTTS-WQ12487MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ575MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ10166MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ7284MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ15027MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ5733MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ10579MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-3127804
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW